SCHEMBL373949

SCHEMBL373949

OCCC1(O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL287854 0.87
SCHEMBL2022523 0.87
SCHEMBL1580146 0.84 CYP2C19 (0.33)
SCHEMBL373953 0.80
SCHEMBL2796087 0.80
SCHEMBL5216304 0.80 KDM4E (0.30)
SCHEMBL2695845 0.80 DRD2 (0.30)
SCHEMBL9305108 0.78
SCHEMBL13619428 0.78 ESR2 (0.31)
SCHEMBL3899125 0.78 ESR2 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025022124-A2 METHODS FOR DEPOLYMERISING AND REPOLYMERISING Epoch Biodesign Ltd (GB) 2025-01-30 WO disclosed
US-20230019236-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2023-01-19 US disclosed
WO-2021127499-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 WO disclosed
EP-3810580-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2021-04-28 EP disclosed
US-10954202-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof ABBVIE INC. (US) 2021-03-23 US disclosed
US-20210009542-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF ABBVIE INC. 2021-01-14 US disclosed
US-10662170-B2 Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2020-05-26 US disclosed
US-10195178-B2 GPR40 agonists in anti-diabetic drug combinations JANSSEN PHARMACEUTICA NV (BE) 2019-02-05 US disclosed
US-10131648-B2 Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2018-11-20 US disclosed
US-20170362196-A1 SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2017-12-21 US disclosed
US-20100239576-A1 AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2010-09-23 US disclosed
WO-2010045095-A1 COMPOUNDS AND METHODS OF USE XI NING (US) 2010-04-22 WO disclosed
US-20100093727-A1 COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2010-04-15 US disclosed
EP-0412110-B1 NOVEL VITAMIN D ANALOGUES LEO PHARM PROD LTD (DK) 1993-07-07 EP disclosed
US-5206229-A Inhibit cell proliferation, antiinflammatory, treating imbalance of immune system LEO PHARMACEUTICAL PRODUCTS LTD (DK) 1993-04-27 US disclosed
US-5194307-A Lamination using heat activated adhesives of epoxy resins MARTIN PROCESSING, INC. (US) 1993-03-16 US disclosed
US-5095077-A High performance epoxy based coverlay and bond ply adhesive with heat activated cure mechanism using polyester-aziridine reaction products MARTIN PROCESSING, INC. (US) 1992-03-10 US disclosed
EP-0412110-A1 NOVEL VITAMIN D ANALOGUES. LEO PHARM PROD LTD (DK) 1991-02-13 EP disclosed
US-4938881-A POLYOLEFIN REACTED WITH MALEIC ANHYDRIDE AND POLYAMINE, METAL SALT OF ORGANIC DITHIOPHOSPHORIC ACID THE LUBRIZOL CORPORATION (US) 1990-07-03 US disclosed
WO-1989010351-A1 NOVEL VITAMIN D ANALOGUES LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMIS (DK) 1989-11-02 WO disclosed